NURS 6630 Midterm Exam Latest 2026 Walden
University | Psychopharmacology & Advanced
Practice Nursing WITH VERIFIED ANSWERS &
DETAILED RATIONALES | GRADED A+
Leave your honest rating⭐⭐⭐⭐⭐
Question 1
A patient asks the PMHNP why they need to take multiple medications for their
psychiatric condition. What is the most appropriate response?
A) "You are not responding to the first medication, so we need to try another one."
B) "Taking multiple medications increases the chance of side effects, but it is
necessary."
C) "Many psychiatric illnesses involve several dysfunctional neurotransmitter
systems in the brain. Often, a single medication may only affect one or two of
the dysfunctional systems. The addition of another medication can work with
the current medication in stabilizing multiple neurotransmitter systems and
help to alleviate your symptoms."
D) "You will eventually be able to stop all medications once your symptoms
improve."
ANSWER>>>C
RATIONALE: Psychiatric illnesses typically involve dysfunction in multiple
neurotransmitter systems (e.g., serotonin, dopamine, norepinephrine, glutamate,
GABA). A single medication may target only one or two systems. Combining
medications can provide synergistic effects by stabilizing multiple systems,
improving efficacy, and potentially allowing lower doses to minimize side effects.
This patient-centered explanation promotes understanding and adherence.
Question 2
Which neurotransmitter system is primarily targeted by most conventional
antipsychotic medications?
,A) Serotonin (5-HT)
B) Dopamine (D2)
C) Norepinephrine (NE)
D) GABA
E) Glutamate
ANSWER>>>B
RATIONALE: Conventional (first-generation) antipsychotics primarily block
dopamine D2 receptors in the mesolimbic and mesocortical pathways. This D2
antagonism is responsible for their antipsychotic efficacy but also causes
extrapyramidal symptoms (EPS) due to D2 blockade in the nigrostriatal pathway.
Atypical antipsychotics also block D2 but with higher 5HT2A affinity, reducing
EPS risk.
Question 3
The PMHNP is teaching a student about antipsychotic medications. Which
response describes how 5HT2A antagonism contributes to reduced risk of
extrapyramidal symptoms (EPS) in atypical antipsychotics?
A) Atypical antipsychotics that are potent D2 antagonists with 5HT2A
antagonist properties have a lower risk of EPS
B) Atypical antipsychotics that are weak D2 antagonists with 5HT2A agonist
properties have a lower risk of EPS
C) Atypical antipsychotics that are potent D2 agonists with 5HT2A antagonist
properties have a lower risk of EPS
D) Atypical antipsychotics that are weak D2 antagonists with 5HT2A agonist
properties have a lower risk of EPS
ANSWER>>>A
RATIONALE: Atypical antipsychotics (e.g., clozapine, risperidone, olanzapine)
have a unique receptor profile with potent D2 antagonism combined with 5HT2A
antagonism. The 5HT2A antagonism increases dopamine release in the
nigrostriatal pathway, which counteracts the EPS caused by D2 blockade. This
combination allows for antipsychotic efficacy with a lower risk of EPS compared
to conventional antipsychotics.
,Question 4
A patient with major depressive disorder is started on an antidepressant. The
PMHNP notices that the patient seems to swing into a hypomanic episode. What
can the PMHNP infer from this behavior?
A) This client may have Bipolar I disorder
B) This client may have Bipolar II disorder
C) This client may have Bipolar III disorder
D) This client may have cyclothymic disorder
ANSWER>>>B
RATIONALE: The development of hypomania during antidepressant treatment
suggests the patient may have Bipolar II disorder. Bipolar II disorder is
characterized by episodes of hypomania (not full mania) and major depression.
Antidepressant-induced hypomania is a common presentation that leads to
diagnosis. Bipolar I disorder involves full manic episodes. Bipolar III disorder is
an older term for antidepressant-induced hypomania.
Question 5
A patient presents with frequent episodes of irritability, impulsivity, and mood
instability. Which statement describes an appropriate treatment for this patient?
A) "The patient could benefit from an antidepressant."
B) "The patient could benefit from an anticonvulsant."
C) "The patient could benefit from a benzodiazepine."
D) "The patient could benefit from a stimulant."
ANSWER>>>B
RATIONALE: Anticonvulsants (mood stabilizers) such as valproate, lamotrigine,
and carbamazepine are effective for mood instability, impulsivity, and irritability.
These symptoms suggest a bipolar spectrum disorder or impulse control disorder.
Antidepressants can worsen mood instability and trigger mania/hypomania.
Benzodiazepines are for acute anxiety. Stimulants can exacerbate irritability and
impulsivity.
, Question 6
A patient is brought to the emergency department after a benzodiazepine overdose.
The PMHNP orders flumazenil. What effect should the PMHNP monitor for?
A) Seizures
B) Withdrawal symptoms
C) Agitation
D) All of the above
ANSWER>>>D
RATIONALE: Flumazenil is a benzodiazepine antagonist that rapidly reverses
benzodiazepine effects. However, it can precipitate acute withdrawal symptoms
including seizures, agitation, and anxiety, especially in patients with chronic
benzodiazepine use or mixed overdoses. Flumazenil should be used with caution
and is not recommended as first-line treatment for benzodiazepine overdose.
Question 7
A patient with schizophrenia is being started on antipsychotic medication. Which
of the following side effects is associated with D2 receptor antagonism in the
nigrostriatal pathway?
A) Extrapyramidal symptoms (EPS)
B) Weight gain
C) Sedation
D) Orthostatic hypotension
E) Hyperprolactinemia
ANSWER>>>A
RATIONALE: D2 receptor blockade in the nigrostriatal pathway leads to EPS
including parkinsonism, dystonia, akathisia, and tardive dyskinesia. Weight gain is
associated with 5HT2C and histamine H1 antagonism. Sedation is primarily due to
histamine H1 antagonism. Orthostatic hypotension is due to alpha-1 adrenergic
antagonism. Hyperprolactinemia is due to D2 blockade in the tuberoinfundibular
pathway.
University | Psychopharmacology & Advanced
Practice Nursing WITH VERIFIED ANSWERS &
DETAILED RATIONALES | GRADED A+
Leave your honest rating⭐⭐⭐⭐⭐
Question 1
A patient asks the PMHNP why they need to take multiple medications for their
psychiatric condition. What is the most appropriate response?
A) "You are not responding to the first medication, so we need to try another one."
B) "Taking multiple medications increases the chance of side effects, but it is
necessary."
C) "Many psychiatric illnesses involve several dysfunctional neurotransmitter
systems in the brain. Often, a single medication may only affect one or two of
the dysfunctional systems. The addition of another medication can work with
the current medication in stabilizing multiple neurotransmitter systems and
help to alleviate your symptoms."
D) "You will eventually be able to stop all medications once your symptoms
improve."
ANSWER>>>C
RATIONALE: Psychiatric illnesses typically involve dysfunction in multiple
neurotransmitter systems (e.g., serotonin, dopamine, norepinephrine, glutamate,
GABA). A single medication may target only one or two systems. Combining
medications can provide synergistic effects by stabilizing multiple systems,
improving efficacy, and potentially allowing lower doses to minimize side effects.
This patient-centered explanation promotes understanding and adherence.
Question 2
Which neurotransmitter system is primarily targeted by most conventional
antipsychotic medications?
,A) Serotonin (5-HT)
B) Dopamine (D2)
C) Norepinephrine (NE)
D) GABA
E) Glutamate
ANSWER>>>B
RATIONALE: Conventional (first-generation) antipsychotics primarily block
dopamine D2 receptors in the mesolimbic and mesocortical pathways. This D2
antagonism is responsible for their antipsychotic efficacy but also causes
extrapyramidal symptoms (EPS) due to D2 blockade in the nigrostriatal pathway.
Atypical antipsychotics also block D2 but with higher 5HT2A affinity, reducing
EPS risk.
Question 3
The PMHNP is teaching a student about antipsychotic medications. Which
response describes how 5HT2A antagonism contributes to reduced risk of
extrapyramidal symptoms (EPS) in atypical antipsychotics?
A) Atypical antipsychotics that are potent D2 antagonists with 5HT2A
antagonist properties have a lower risk of EPS
B) Atypical antipsychotics that are weak D2 antagonists with 5HT2A agonist
properties have a lower risk of EPS
C) Atypical antipsychotics that are potent D2 agonists with 5HT2A antagonist
properties have a lower risk of EPS
D) Atypical antipsychotics that are weak D2 antagonists with 5HT2A agonist
properties have a lower risk of EPS
ANSWER>>>A
RATIONALE: Atypical antipsychotics (e.g., clozapine, risperidone, olanzapine)
have a unique receptor profile with potent D2 antagonism combined with 5HT2A
antagonism. The 5HT2A antagonism increases dopamine release in the
nigrostriatal pathway, which counteracts the EPS caused by D2 blockade. This
combination allows for antipsychotic efficacy with a lower risk of EPS compared
to conventional antipsychotics.
,Question 4
A patient with major depressive disorder is started on an antidepressant. The
PMHNP notices that the patient seems to swing into a hypomanic episode. What
can the PMHNP infer from this behavior?
A) This client may have Bipolar I disorder
B) This client may have Bipolar II disorder
C) This client may have Bipolar III disorder
D) This client may have cyclothymic disorder
ANSWER>>>B
RATIONALE: The development of hypomania during antidepressant treatment
suggests the patient may have Bipolar II disorder. Bipolar II disorder is
characterized by episodes of hypomania (not full mania) and major depression.
Antidepressant-induced hypomania is a common presentation that leads to
diagnosis. Bipolar I disorder involves full manic episodes. Bipolar III disorder is
an older term for antidepressant-induced hypomania.
Question 5
A patient presents with frequent episodes of irritability, impulsivity, and mood
instability. Which statement describes an appropriate treatment for this patient?
A) "The patient could benefit from an antidepressant."
B) "The patient could benefit from an anticonvulsant."
C) "The patient could benefit from a benzodiazepine."
D) "The patient could benefit from a stimulant."
ANSWER>>>B
RATIONALE: Anticonvulsants (mood stabilizers) such as valproate, lamotrigine,
and carbamazepine are effective for mood instability, impulsivity, and irritability.
These symptoms suggest a bipolar spectrum disorder or impulse control disorder.
Antidepressants can worsen mood instability and trigger mania/hypomania.
Benzodiazepines are for acute anxiety. Stimulants can exacerbate irritability and
impulsivity.
, Question 6
A patient is brought to the emergency department after a benzodiazepine overdose.
The PMHNP orders flumazenil. What effect should the PMHNP monitor for?
A) Seizures
B) Withdrawal symptoms
C) Agitation
D) All of the above
ANSWER>>>D
RATIONALE: Flumazenil is a benzodiazepine antagonist that rapidly reverses
benzodiazepine effects. However, it can precipitate acute withdrawal symptoms
including seizures, agitation, and anxiety, especially in patients with chronic
benzodiazepine use or mixed overdoses. Flumazenil should be used with caution
and is not recommended as first-line treatment for benzodiazepine overdose.
Question 7
A patient with schizophrenia is being started on antipsychotic medication. Which
of the following side effects is associated with D2 receptor antagonism in the
nigrostriatal pathway?
A) Extrapyramidal symptoms (EPS)
B) Weight gain
C) Sedation
D) Orthostatic hypotension
E) Hyperprolactinemia
ANSWER>>>A
RATIONALE: D2 receptor blockade in the nigrostriatal pathway leads to EPS
including parkinsonism, dystonia, akathisia, and tardive dyskinesia. Weight gain is
associated with 5HT2C and histamine H1 antagonism. Sedation is primarily due to
histamine H1 antagonism. Orthostatic hypotension is due to alpha-1 adrenergic
antagonism. Hyperprolactinemia is due to D2 blockade in the tuberoinfundibular
pathway.
